Elongation Factor-2, a Th1 Stimulatory Protein of Leishmania donovani, Generates Strong IFN-γ and IL-12 Response in Cured Leishmania-Infected Patients/Hamsters and Protects Hamsters against Leishmania Challenge
Authors:
Open Access
- 15 December 2011
- journal article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 187 (12) , 6417-6427
Abstract
In visceral leishmaniasis, Th1 types of immune responses correlate with recovery from and resistance to disease, and resolution of infection results in lifelong immunity against the disease. Leishmanial Ags that elicit proliferative and cytokine responses in PBMCs from cured/exposed/Leishmania patients have been characterized through proteomic approaches, and elongation factor-2 is identified as one of the potent immunostimulatory proteins. In this study, we report the cloning and expression of Leishmania donovani elongation factor-2 protein (LelF-2) and its immunogenicity in PBMCs of cured/exposed Leishmania-infected patients and hamsters (Mesocricetus auratus). Leishmania-infected cured/exposed patients and hamsters exhibited significantly higher proliferative responses to recombinant Lelf-2 (rLelF-2) than those with L. donovani-infected hosts. The soluble L. donovani Ag stimulated PBMCs of cured/exposed and Leishmania patients to produce a mixed Thl/Th2-type cytokine profile, whereas rLelF-2 stimulated the production of IFN-γ, IL-12, and TNF-α but not IL-4 or IL-10. Further, rLelF-2 downregulated LPS-induced IL-10 as well as soluble L. donovani Ag-induced IL-4 production by Leishmania patient PBMCs. The immunogenicity of rLelF-2 was also checked in hamsters in which rLelF-2 generates strong IL-12– and IFN-γ–mediated Th1 immune response. This was further supported by a remarkable increase in IgG2 Ab level. We further demonstrated that rLelF-2 was able to provide considerable protection (∼65%) to hamsters against L. donovani challenge. The efficacy was supported by the increased inducible NO synthase mRNA transcript and Th1-type cytokines IFN-γ, IL-12, and TNF-α and downregulation of IL-4, IL-10, and TGF-β. Hence, it is inferred that rLelF-2 elicits a Th1 type of immune response exclusively and confers considerable protection against experimental visceral leishmaniasis.Keywords
This publication has 49 references indexed in Scilit:
- Estimation of Under-Reporting of Visceral Leishmaniasis Cases in Bihar, IndiaThe American Journal of Tropical Medicine and Hygiene, 2010
- Molecular architecture of leishmania EF-1α reveals a novel site that may modulate protein translation: A possible target for drug developmentBiochemical and Biophysical Research Communications, 2007
- Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental modelsParasitology Research, 2005
- Molecular cloning, biochemical and structural analysis of elongation factor-1α from Leishmania donovani: comparison with the mammalian homologueBiochemical and Biophysical Research Communications, 2003
- NITRIC OXIDE AND MACROPHAGE FUNCTIONAnnual Review of Immunology, 1997
- Interleukin-12 and its role in the generation of TH1 cellsImmunology Today, 1993
- IL-12: Initiation Cytokine for Cell-Mediated ImmunityScience, 1993
- Resistance to Leishmania major infection correlates with the induction of nitric oxide synthase in murine macrophagesEuropean Journal of Immunology, 1991
- Macrophage activation by interferon‐γ from host‐protective T cells is inhibited by interleukin (IL) 3 and IL 4 produced by disease‐promoting T cells in leishmaniasisEuropean Journal of Immunology, 1989
- Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.Proceedings of the National Academy of Sciences, 1979